It is an unapproved investigational compound that did not complete clinical development, has not been authorized by Health Canada for any human or veterinary indication, and is not intended to diagnose, treat, cure, or prevent any disease
(Lausanne) 16, 1520362
Semaglutide, the active ingredient in Wegovy, has demonstrated a 15% average body weight reduction in clinical trials when combined with lifestyle modifications
The synthesis of NAA, although significant in the brain, is not exclusive to this tissue
Key Highlights: 1
Pharmacol Res Perspect 3:e00136 Pai V, Paneerselvam A, Mukhopadhyay S et al (2014) A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)